引用次数
引用: 5,828
H-指数: 38
I10-指数 : 121
出版物: 460
Major histocompatibility complex antigens in Turkish children with steroid-responsive nephrotic syndrome.
Sevgi Mir , Necil Kutukculer , Kaan Kavakli
Pediatric Nephrology 8 ( 2) 259 -260
2
1994
Effects of iron(II) salts and iron(III) complexes on trace element status in children with iron-deficiency anemia.
Eser Yildirim Sözmen , Kaan Kavakli , Bilin Çetinkaya , Yasemin Delen Akçay
Biological Trace Element Research 94 ( 1) 79 -86
13
2003
Recombinant Porcine Factor VIII in Patients with Congenital Hemophilia a with Inhibitors Undergoing Surgery: Phase 3, Multicenter, Single Arm, Open-Label Study
Christian Pfrepper , Paolo Radossi , Jerzy Windyga , Kaan Kavakli
Blood 138 2109
2021
Source of Factor VIII Replacement (PLASMATIC OR RECOMBINANT) and Incidence of Inhibitory Alloantibodies in Previously Untreated Patients with Severe Hemophilia a: The Multicenter Randomized Sippet Study
Mehran Karimi , Veronica Soto Arellano , Monica Cerqueira , Nadia P Ewing
Endocrine Complications in Patients with β‐thalassemia Major
Yeşim Aydinok , Sukran Darcan , Aziz Polat , Kaan Kavakli
Journal of tropical pediatrics 48 ( 1) 50 -54
118
2002
Long-term efficacy and safety of subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors
Amy D Shapiro , Pantep Angchaisuksiri , Jan Astermark , Gary Benson
Blood Advances 6 ( 11) 3422 -3432
33
2022
Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b open-label trial
Steven W Pipe , Peter Collins , Christophe Dhalluin , Gili Kenet
Blood 143 ( 14) 1355 -1364
9
2024
Emicizumab prophylaxis in infants with severe hemophilia A without Factor VIII inhibitors: results from the primary analysis of the HAVEN 7 Study
Steven Pipe , Peter Collins , Christophe Dhalluin , Gili Kenet
Blood 142 505 -505
5
2023
A risk haplotype including TNFA-308A in the promoter region of the gene for TNF-a influences the risk of inhibitor development in patients with hemophilia A.
Jan Astermark , J Oldenburg , Joyce Carlson , A Pavlova
Blood 108 ( 12) 3739 -3745
2006
Efficacy and safety of fidanacogene elaparvovec in adults with moderately severe or severe hemophilia B: results from the phase 3 BENEGENE-2 gene therapy trial
Adam Cuker , Hazzaa Alzahrani , Jan Astermark , Laurent Frenzel
ISTH
5
2023
Hemophilia research and clinical care needs: Regional variation in future priorities
Pantep Angchaisuksiri , Jeannett Dimsits , Alfonso Iorio , Kaan Kavakli
HAEMOPHILIA 22 51 -51
2016
Are all licensed haemostatic agents for haemophilia therapy accessible to patients?
Karin Berger , Angelika Batorova , Rhonda Bohn , Matteo di Minno
Haemophilia 28 ( 6)
2022
Efficacy and safety of a VWF/FVIII concentrate (wilate®) in inherited von Willebrand disease patients undergoing surgical procedures
A Srivastava , M Serban , S Werner , BA Schwartz
Haemophilia 23 ( 2) 264 -272
17
2017
Management of haemophilia A with inhibitors: a regional cross‐talk
Flora Peyvandi , Kaan Kavakli , Amal El‐Beshlawy , Savita Rangarajan
Haemophilia 28 ( 6) 950 -961
7
2022
Fitusiran prophylaxis in people with hemophilia A or B who switched from prior BPA/CFC prophylaxis: the ATLAS-PPX trial
Gili Kenet , Beatrice Nolan , Bulent Zulfikar , Bulent Antmen
Blood 143 ( 22) 2256 -2269
2
2024
S303: A PHASE 3 STUDY (ATLAS-PPX) TO EVALUATE EFFICACY AND SAFETY OF FITUSIRAN IN PEOPLE WITH HAEMOPHILIA A OR B WHO HAVE SWITCHED FROM PRIOR CLOTTING FACTOR CONCENTRATE OR BYPASSING AGENT PROPHYLAXIS
Gili Kenet , Beatrice Nolan , Bulent Zulfikar , Bulent Antmen
HemaSphere 7 ( S3) e643526e -e643526e
1
2023
Efficacy, Safety, and Presurgical Pharmacokinetics of Recombinant VWF (rVWF) in Patients With Severe VWD Who Are Undergoing Elective Surgical Procedures
Flora Peyvandi , Andrey Mamaev , Jiaan-Der Wang , Oleksandra Stasyshyn
Recombinant porcine factor VIII in patients with congenital haemophilia A with inhibitors undergoing surgery: Phase 3, single‐arm, open‐label study
Christian Pfrepper , Paolo Radossi , Jerzy Windyga , Kaan Kavakli
Haemophilia
2024
Pharmacokinetics, efficacy, and safety of high-purity factor X for the prophylactic treatment of hereditary factor X deficiency
Ri Liesner , James N Huang , Kaan Kavakli , Steven K Austin
Wiley
1
2018
Outcome of Joint Functions in Hemophilic Patients: A Twelve Year Retrospective Study
Kazım ÇAPACI , Can Balkan , Deniz Yilmaz , Yılmaz AY
Journal of Rheumatology and Medical Rehabilitation 21 ( 2) 29 -36
2010